Page last updated: 2024-11-06

pentazirinocyclodiphosphathiazene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pentazirinocyclodiphosphathiazene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72601
CHEMBL ID25804
MeSH IDM0107914

Synonyms (23)

Synonym
soaz
77680-87-6
nsc-321222
1h-1,4,6,3,5-thiatriazadiphosphorine, 1,3,3,5,5-pentakis(1-aziridinyl)-3,3,5,5-tetrahydro-, 1-oxide
nsc321222
pentazirinocyclodiphosphathiazene
pentazirino-cyclo-diphosphathiazene
1h-1,2,4,6,3,5-thiatriazadiphosphorine, 3,3,5,5-tetrahydro-1,3,3,5,5-pentakis(1-aziridinyl)-,1-oxide
brn 5652899
nsc 321222
1,3,3,5,5-pentaaziridino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide
1,3,3,5,5-pentazridino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide
1h-1,2,4,6,3,5-thiatriazadiphosphorine, 1,3,3,5,5-pentakis(1-aziridinyl)-3,3,5,5-tetrahydro-, 1-oxide
pentakis(aziridino)thiatriazadiphosphorine oxide
CHEMBL25804
6486l9a934 ,
unii-6486l9a934
DTXSID50228313
pentaaziridinocyclodiphosphathiazene
1.lambda.4-1,2,4,6,3,5-thiatriazadiphosphorine, 1,3,3,5,5-pentakis(1-aziridinyl)-3,3,5,5-tetrahydro-, 1-oxide
IQMLWPPOVFMTOU-UHFFFAOYSA-N
Q27263717
PD159847

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The LD50 values in rodents were 325 mg kg-1 for male mice, 450 mg kg-1 for female mice, 100 mg kg-1 for male rats and 82 mg kg-1 for female rats."( Acute toxicity study of 1,3,3,5,5-pentaziridino-1-thia-2,4,6-triaza-3,5-diphosp horine-1-oxide (a new antitumor agent with an inorganic ring) in mice, rats and dogs.
Kirihara, Y; Kuwata, M; Morita, K; Nakano, S; Yamashita, K, 1984
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" The method is suitable for biological samples and therefore has been proposed for clinical pharmacokinetic studies as well as for the determination of patterns of SOAz distribution in several organs of the mouse."( [Gas-liquid chromatographic assay of a new antineoplastic agent, 1,3,3,5,5-pentakis-(azaridino)lambda 6-2,4,6,3 lambda 5, 5 lambda 5-thiatriazadiphosphorine-1-oxide. Application to pharmacokinetic studies].
Cattan, A; Coninx, P; Deltour, G; Enger, A; Fournaise, R; Jezekova, D, 1984
)
0.27
"A sensitive method, based on capillary gas chromatography using a thermionic detector, has been developed for the new antitumor agent pentakis(aziridino)-thiatriazadiphosphorine-oxide, (NPAz2)2NSOAz ('SOAz'), in order to obtain pharmacokinetic data from patients receiving this drug IV in clinical trials."( Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man.
Beneken genaamd Kolmer, MH; Rodenhuis, S; Uges, DR; van de Grampel, JC, 1983
)
0.27
"2 min a terminal phase with a dose-independent half-life of 203 +/- 17 min occurred."( Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'.
Beneken genaamd Kolmer, MH; Mulder, NH; Rodenhuis, S; Scaf, AH; Sleijfer, DT; Uges, DR; van de Grampel, JC, 1983
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The dosed animals showed diarrhoea and decreased movement in the three species, and emaciation and loss of body weight in mice and rats."( Acute toxicity study of 1,3,3,5,5-pentaziridino-1-thia-2,4,6-triaza-3,5-diphosp horine-1-oxide (a new antitumor agent with an inorganic ring) in mice, rats and dogs.
Kirihara, Y; Kuwata, M; Morita, K; Nakano, S; Yamashita, K, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID96594Tested in vivo for 50% lethal dose in L1210 mouse leukemia cells1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
AID120862Compound was tested for percent median survival time of drug-treated mice over that of untreated control mice at dose of 175 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
AID120864Tested for percent median survival time of drug-treated mice over that of untreated control mice at dose of 200 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
AID98668In vitro inhibition dose (cytostatic activity) in L1210 mouse leukemia cells1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]